6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005539-10-DE (EUCTR)	29/04/2014	18/12/2013	Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.	Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation	Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A	Merz Pharmaceuticals GmbH	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3	United States;Poland;Germany
2	NCT02419313 (ClinicalTrials.gov)	August 2012	27/1/2014	Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach	Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach	Parkinson;Tremor	Drug: incobotulinumtoxinA;Drug: Saline	Yale University	NULL	Completed	18 Years	N/A	All	33	Phase 2	United States
3	NCT01565395 (ClinicalTrials.gov)	March 2012	26/3/2012	Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)	Parkinson Disease;Amyotrophic Lateral Sclerosis	Drug: Incobotulinum Toxin A;Drug: placebo	Beth Israel Deaconess Medical Center	Merz Pharmaceuticals	Withdrawn	20 Years	80 Years	All	0	Phase 2	United States
4	NCT01653132 (ClinicalTrials.gov)	March 2012	25/7/2012	Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism	Sialorrhea	Drug: Incobotulinum Toxin A;Drug: Placebo	Beth Israel Deaconess Medical Center	NULL	Completed	18 Years	90 Years	All	10	Phase 2	United States
5	NCT00909883 (ClinicalTrials.gov)	September 2009	19/5/2009	Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)	Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)	Parkinson's Disease;Foot Dystonia	Drug: Botulinum Toxin: Xeomin;Drug: Placebo	University Hospital, Clermont-Ferrand	Merz Pharma France	Recruiting	30 Years	75 Years	Both	45	Phase 3	France